Overview
Status
Active
Registry date
2001-07-27
Registered address
Nowotomyska 33, 64-310 Lwówek, Poland
Electronic delivery address
AE:PL-65728-94886-GUFDF-14
Financials
Revenue history (in k)
Filing timeliness
Financial statements were filed on time, on average 22 days early. 1 of 6 audited by a statutory auditor.
- 202525/06/2026
- 202417/06/2025
- 202314/06/2024
- 202207/06/2023
- 202111/07/2022
- 202006/10/2021
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Revenue
This companyUSD 5.59mMedianUSD 1.06mAverageUSD 22.40m
Net profit
This companyUSD 165.82kMedianUSD 37.33kAverageUSD 880.24k
Operating costs
This companyUSD 5.42mMedianUSD 922.77kAverageUSD 21.08m
Assets
This companyUSD 2.07mMedianUSD 608.93kAverageUSD 11.85m
Industry
Trademarks
Rolvet Józef i Barbara Napierała currently holds no active trademarks with the Polish Patent Office. 2 marks have expired or were not registered. The first mark was filed in 1997.
| Mark | Number | Classes | Status | Protected until | |
|---|---|---|---|---|---|
| ROLVET marka zdrowia | Z.331374 | 1, 5, 10 | Refused | – | |
| ROLVET V | Z.181783 | 5 | Expired | – |
| Mark | Protected until | |
|---|---|---|
| ROLVET marka zdrowia | – | |
| ROLVET V | – |
Ownership
| Owner |
|---|
Barbara Urszula Napierałaage 78 |
Józef Napierałaage 77 |
Dagmara Anna Semrauage 53 |
Manner of representation
Independent representation.
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 1996-08-16.
40 1090 1388 0000 0000 3800 9240
77 1090 1362 0000 0001 3490 9597
63 1090 1388 0000 0001 1127 7000
Debt
No entries in the National Debtors Register (KRZ).
Real estate
| Type | Amount |
|---|---|
Buildings and premises | PLN 1,697PLN 1,697 |
Public aid
6 public aid cases recorded, with a total value of $530,707.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jul 22, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $517.5K$517,494 | Polski Fundusz Rozwoju S.A. | |
| Jun 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $2,049$2,049 | Prezes Zakładu Ubezpieczeń Społecznych | |
| May 30, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $1,897$1,897 | Prezes Zakładu Ubezpieczeń Społecznych |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| MedaseptS.A. | $8,612,031.18 | medasept.pl | ||
| PHS Hospitalsp. z o.o. + limited partnership | $1,933,301.24 | phs.med.pl | ||
| Sonomedical Pluciński, Wojciechowski, Wituskisp. j. | $1,264,523.63 | sonomedical.pl | ||
| Medaidsp. z o.o. | $1,034,514.88 | medaid.pl | ||
| Meditechsp. z o.o. | $934,565.46 | meditech.pl | ||
| PNN Pharmaceuticals sp. z o.o.sp. k. | $267,897.16 | pnn.com.pl | ||
| Medicallenssp. z o.o. | $179,960.83 | medicallens.com | ||
| Integris Medical Polskasp. z o.o. | $159,033.76 | integrismedical.pl | ||
| Aptekssp. z o.o. | $13,537.42 | apteks.com | ||
| HA Technologiessp. z o.o. | $206.67 | amalian.pl |
FAQ
The main business activity of Rolvet Józef i Barbara Napierała focuses on wholesale of pharmaceutical goods.
The company was registered in the Polish National Court Register (KRS) on July 27, 2001.
The headquarters is located at: Nowotomyska 33, 64-310 Lwówek.
The legal form of this entity is a general partnership (sp.j.).
The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.
In 2024, the company generated total revenue of $7,166,676, representing a decrease of 3.5% compared to 2023.
Yes, the company recorded a net profit of $95,251 in 2024.
The largest operating cost category falls under cost of goods and materials sold. This category amounted to $6,667,713 in 2024, representing 95% of all operating expenses.
Last updated: 2026-06-25